



WILSONS
ADVISORY



Research Company Disclosures

March 2024

Research Company Disclosures

Company name	Stock Code	Regulatory Disclosure
Aroa Biosurgery Limited	ARX.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the July 2021 institutional placement of Aroa Biosurgery Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the June 2020 initial public offering of Aroa Biosurgery Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Collins Foods Limited	CKF.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter to the March 2017 Placement and Joint Lead Manager and Underwriter in the July 2017 Accelerated Non-Renounceable Entitlement Offer of Collins Foods Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Clarity Pharmaceuticals Limited	CU6.ASX	<p>This report is part of the ASX Equity Research Scheme FY24 whereby a fee has been paid to Wilsons by ASX Operations Pty Limited (ASX) for the publication of research on Clarity Pharmaceuticals (Company, Clarity). Wilsons maintains that the independence of the research written in this report remains intrinsic to the research published and the ASX is not involved in the compilation of this report. All prescribed ratings and target prices in the report have been influenced by neither the ASX, nor the Company. The research analyst compiling this research has not been directly compensated by the ASX in the production of this research and the analyst attests to the objectivity and independence of the research written.</p> <p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the March 2024 institutional placement of Clarity Pharmaceuticals Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

Company name	Stock Code	Regulatory Disclosure
EBR Systems Inc	EBR.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as a Joint Lead Manager to the June 2023 Institutional Placement and Joint Lead Manager to the October 2021 Initial Public Offer of EBR Systems Inc securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.
EML Payments Limited	EML.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Co-Manager in the November 2019 placement of EML Payments Ltd securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.
Etherstack PLC	ESK.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager in the December 2020 institutional placement of Etherstack PLC securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.
EQT Holdings	EQT.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Co-Lead Manager in the August 2022 placement and entitlement offer of EQT Holdings Ltd securities for which it received fees or will receive fees for acting in this capacity.
Envirosuite Ltd	EVS.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the December 2021 placement of Envirosuite Ltd securities for which it received fees or will receive fees for acting in this capacity.

Company name	Stock Code	Regulatory Disclosure
Immutep Ltd	IMM.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and underwriter in the May 2023 pro rata accelerated non-renounceable entitlement offer and Institutional Placement of Immutep Limited Securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.
ImpediMed Limited	IPD.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as acted as Joint Lead Manager in the May 2023 Institutional Placement and Share Purchase Plan of ImpediMed Limited Securities; Joint Lead Manager in the October 2021 Institutional Placement and Joint Lead Manager and Underwriter in the July 2019 and April 2020 Entitlement Offer of ImpediMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report. Wilsons restricts research analysts from trading in securities for which they write research. Other Wilsons employees may hold interests in the company, but none of those interests are material. Wilsons further advises that at the date of this report, neither Wilsons Advisory and Stockbroking Limited or Wilsons Corporate Finance Limited have any material interests in the company.
Janison Education Group Limited	JAN.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the June 2021 Institutional Placement and Share Purchase Plan of Janison Education Group Ltd securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.
Noni B Limited/Mosaic Brands	MOZ.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager and Underwriter in the May 2018 placement and entitlement offer of Noni B Limited securities and Financial Advisor on the November 2019 acquisition of EziBuy Limited for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager and Underwriter in the September 2021 capital raise of convertible notes of Mosaic Brands Limited. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.

Company name	Stock Code	Regulatory Disclosure
Nido Education Ltd	NDO.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the October 2023 Initial Public Offering of Nido Education Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.
Nuchev Limited	NUC.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Sole Lead Manager to the May 2023 pro rata non-renounceable entitlement offer for Nuchev Limited securities; acted as Sole Lead Manager and Underwriter in the December 2019 IPO and the Lead Manager and Underwriter in the July 2020 capital raising of Nuchev Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.
Next Science Ltd	NXS.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the August 2023 Institutional Placement for Next Science securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the February 2022 two tranche institutional placement ("Placement") for Next Science securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.
Pacific Smiles Group Limited	PSQ.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the March 2021 placement of Pacific Smiles Group Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.

Company name	Stock Code	Regulatory Disclosure
Plenti Group Limited	PLT.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Sole Lead Manager and Underwriter in the August 2020 initial public offering of Plenti Group Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.
Pinnacle Investment Management Group Limited	PNI.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter to the November 2021 Institutional Placement. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Underwriter in the September 2021 and March 2021 Dividend Reinvestment Plans for Pinnacle Investment Management Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the July 2018 placement of Pinnacle Investment Management Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.
ReadyTech Holdings Limited	RDY.ASX	Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the April 2019 IPO and Lead Manager and Underwriter in the November 2020 Placement of ReadyTech Holdings Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.

Company name	Stock Code	Regulatory Disclosure
Rural Funds Group	RFF.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager for the July 2021 Equity raising of Rural Funds Group securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager for the July 2018 Entitlement Offer of Rural Funds Group securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Co-Lead Manager and Underwriter in the June 2017 Entitlement Offer of Rural Funds Group securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Rumble Resources Ltd	RTR.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Sole Lead Manager for the August 2023 placement of Rumble Resources Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Ridley Corporation Ltd	RIC.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 has been appointed as broker for the Ridley Corporation Limited Securities on- market buyback, announced September 2022, for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

Company name	Stock Code	Regulatory Disclosure
SomnoMed Limited	SOM.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager and Underwriter in the August 2023 Institutional Placement and pro rata accelerated non-renounceable entitlement offer of SomnoMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager and Underwriter in the March 2020 accelerated pro-rata non-renounceable entitlement offer of SomnoMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the February 2018 accelerated pro-rata non-renounceable entitlement offer of SomnoMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited acted as Lead Manager and Underwriter in the May 2016 placement of SomnoMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Telix Pharmaceuticals Limited	TLX.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager to the Telix Pharmaceuticals Limited January 2022 Institutional Placement and SPP for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Co-Manager to the Telix Pharmaceuticals Limited July 2019 Placement for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Joint Underwriter to the Telix Pharmaceuticals Limited November 2017 IPO for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>



Wilsons Advisory & Stockbroking Ltd

www.wilsonsadvisory.com.au

For your nearest office
free call 1300 655 015